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We evaluated the impact of age and remission status on 242 consecutive patients who underwent allogeneic
hematopoietic cell transplantation for acute myeloid leukemia (AML) in our program between 1999 and 2011.
Median age of all patients was 48 years (range, 18 to 71). Based on age and remission status, patients were
divided into 4 groups: ﬁrst complete remission (CR1) age <60 years (n ¼ 116), second complete remission
(CR2) age <60 years (n ¼ 78), CR1 age 60 years (n ¼ 32), and CR2 age 60 years (n ¼ 16). Donors were
matched related (n ¼ 155, 64%) or matched unrelated (n ¼ 87, 36%). Median follow-up of survivors was
65 months (range, 12 to 145). In a univariate analysis, 3-year overall survival rates of the 4 groups were 57%,
43%, 39%, and 16% (P ¼ .003), respectively. In a multivariable analysis, hazard ratios of nonrelapse mortality
and survival were 2.08 (P ¼ .06) and 1.52 (P ¼ .23), respectively, in patients 60 years in CR2 compared with 
60 years in CR1. Although a plateau in survival was observed for patients 60 years in CR1 similar to those
<60 years in CR1 and CR2, no long-term survivors were seen in patients 60 years in CR2. Our data suggest
disappointing outcomes in AML patients 60 years of age transplanted in CR2. Therefore, if a transplant is
indicated, early referral is recommended in patients 60 years with AML.
Crown Copyright  2014 Published by Elsevier Inc. on behalf of American Society for Blood and Marrow
Transplantation. All rights reserved.INTRODUCTION
Allogeneic hematopoietic cell transplantation (HCT)
offers curative potential in the treatment of patients with
acute myeloid leukemia (AML). The advantage of HCT
compared with conventional chemotherapy for subgroups of
AML patients was previously reviewed [1]. A meta-analysis
demonstrated improved survival in patients aged 
60 years with AML in ﬁrst complete remission (CR1) with
intermediate or adverse cytogenetics at diagnosis who un-
derwent HCT compared with those who received conven-
tional chemotherapy [2]. The beneﬁt of HCT for younger
patients was recently demonstrated in patients with AML in
second complete remission (CR2), who had intermediate- or
adverse-risk cytogenetics [3].
The outcomes of younger patients with AML have
improved in the last 2 decades. Factors contributing to
improved outcomes in younger patients with AML include
improvements in supportive care and increased utilization as
well as optimization of HCT [4]. Although outcomes of
younger patients with AML have improved, no signiﬁcant
improvement has been observed in older patients [5]. A case-edgments on page 479.
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13.12.560controlled study showed improved outcome of patients ages
60 to 70 years treated with HCT compared with chemo-
therapy alone [6].
In transplant recipients, some studies demonstrated that
older age alone did not signiﬁcantly affect survival post-
transplant but remission status did, with a signiﬁcant
advantage for patients transplanted in CR1 [7]. On the con-
trary, another study showed that remission status did not
affect survival of patients with AML post-HCT using reduced-
intensity conditioning (RIC); however, this study included
patients with a wide range of ages, including younger pa-
tients [8]. A Center for International Blood and Marrow
Transplant Research study showed that older patients un-
dergoing RIC HCT for AML in CR1 beneﬁt as equally as
younger patients [9]. Reports in the literature concerning the
beneﬁt of older patients (60 years) in CR2 are conﬂicting.
Some studies demonstrated a lack of signiﬁcant effect of
patient age on outcome [10,11], whereas others found that
patient age55 years is a predictor of poor survival after HCT
for AML in CR2 [12].
We evaluated the impact of age in association with
remission status on the outcomes of 242 consecutive patients
who underwent HCT for AML in our program from 1999 to
2011. We report that HCT offers a curative potential to AML
patients 60 years in CR1 similar to younger patients;
however, the outcomes in patients 60 years in CR2 are
disappointing. We also explore the causes for poor outcomesc. on behalf of American Society for Blood and Marrow Transplantation. All
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METHODS
Patients
The study population consisted of 242 consecutive patients aged 18 to
71 years undergoing ﬁrst allogeneic transplant for AML in CR1 and CR2
from matched related (n ¼ 155) or matched unrelated donors (n ¼ 87)
between January 1999 and June 2011 at Princess Margaret Cancer Centre,
Toronto, Ontario, Canada. Among these patients, 194 (80%) were age<60 at
transplant, and 48 (20%) were age 60 years. Data were collected from the
Electronic Patient Records of the hospital as well as the Bone Marrow
Transplant Program database. The study was approved by the Cancer
Registry Data Access Committee and the Research Ethics Board of the
University Health Network/Princess Margaret Cancer Centre (REB no. 12-
0048-CE).
Data
Data collected and subsequently analyzed involved a number of pre-
transplant variables, including age, gender, cytogenetic risk at diagnosis,
conditioning regimen, hematopoietic progenitor cell source, related or un-
related donor status, and cytomegalovirus serostatus of donor and recipient.
Based on age and remission status, patients were divided into 4 groups: CR1
age <60 years, CR2 age <60 years, CR1 age 60 years, and CR2 age 
60 years. Cytogenetics at diagnosis was characterized as favorable, inter-
mediate, unfavorable, and unknown risk as previously described [13].
The HCT-comorbidity index was calculated for all transplanted patients
retrospectively from the pretransplant investigations and chart review.
Comorbidities were analyzed as presenting with either a low-risk (0 to 2) or
high-risk score (3) [14].
Conditioning Regimens and Graft-versus-Host Disease Prophylaxis
Patients were conditioned either withmyeloablative conditioning or RIC
regimens. The decision to offer RIC was primarily based on patient age and
the presence of signiﬁcant comorbidities, as previously described [15].
Classiﬁcation of the intensity of conditioning regimen was based on the
Center for International Blood and Marrow Transplant Research suggested
criteria [16]. The myeloablative conditioning regimens were subdivided into
2 groups. First, those used from 1999 to 2006 included busulfan 3.2 mg/kg
for 4 days and cyclophosphamide 60 mg/kg for 2 days cyclophosphamide
60 mg/kg for 2 days and total body irradiation 12 Gy. Second, since 2006
patients received conditioning with ﬂudarabine 50 mg/m2 for 4 days,
busulfan 3.2 mg/kg for 4 days, and total body irradiation 400 cGy in 2
fractions.
RIC regimens used between 1999 and2006 included combinations of
ﬂudarabine 30 mg/m2 for 4 to 5 days with busulfan 3.2 mg/kg for 2 days or
with total body irradiation 200 cGy [17]. Since 2006 patients were condi-
tioned with ﬂudarabine 30 mg/m2 for 4 days, busulfan 3.2 mg/kg for 2 days,
and total body irradiation 200 cGy.
Graft-versus-host disease prophylaxis consisted of cyclosporine A,
combined with either methotrexate (15 mg/m2 on HCT day þ1 and 10 mg/
m2 on HCT days þ3, þ6, and þ11; n ¼ 124) or mycophenolate mofetil (given
for 28 days post-transplant; n ¼ 60). Serotherapy using low-dose alemtu-
zumab or antithymocyte globulin was used in combination with cyclo-
sporine A in 58 patients undergoing unrelated donor transplantation.
Deﬁnitions of Clinical Endpoints
For the purpose of this study, complete remission (CR) was deﬁned as
achievement of a bone marrowwith<5% blasts and count recovery. Relapse
was deﬁned as 5% blasts in a bone marrow aspirate or peripheral blood or
the development of extramedullary leukemia after transplant. Overall sur-
vival (OS) times were measured from the date of HCT until death from any
cause. Alive patients were censored on the date of their last follow-up.
Leukemia-free survival (LFS) was deﬁned as the time from transplantation
to relapse or death from any cause. Nonrelapse mortality (NRM) was
calculated as death without evidence of disease relapse.
Statistical Analysis
Patient demographics and treatment-related outcomes were reported
using descriptive statistics. Categorical variables were summarized with
counts and percentages. Continuous variables were summarized with
means and/or medians with ranges. Data were updated as of June 2012.
Contingency statistics using the chi-square test or Fisher’s exact test (as
appropriate) were performed for the comparison of distribution of the
variables between the four groups deﬁned by CR status/age combination.
Analysis of variance was used to compare the continuous outcome age at
transplant among the 4 groups.The main outcome variables of interest were death due to any cause OS,
LFS, cumulative incidence of relapse CIR, and cumulative incidence of NRM.
OS and LFS were calculated using the Kaplan-Meier product-limit method.
The log-rank test was used as a univariate analysis to compare the levels of
the 4 groups consisting of age/CR status combination as well as baseline
patient characteristics. CIR and NRM were calculated using the competing
risk method based on Pepe and Mori’s method [18]. The Fine and Gry
method for competing risks was used for univariate and multivariable an-
alyses in comparing CIR and NRM.
Because of the small sample size, we performed a limited multivariable
analysis using clinically relevant factors. The following factors were
analyzed: age/remission status (<60 in CR1, <60 in CR2, 60 in CR1, and
60 in CR2), donor type (related versus unrelated), conditioning regimen
(myeloablative conditioning versus RIC), HCT-comorbidity index score (0 to
2 versus3), and time period of HCT (before or after 2006, which was when
different conditioning regimens were used as described previously). Results
were considered signiﬁcant if P < .05. Statistical analyses were performed
using version 9.2 of the SAS system and user’s guide (SAS Institute, Inc., Cary,
NC) and R version 2.14.0, the R foundation for statistical computing.
RESULTS
Patient and Transplant Characteristics
Baseline patient, disease, and transplant-related charac-
teristics are summarized in Table 1. Two hundred forty-two
patients with a median age of 48 years (range, 18 to 71)
underwent transplantation. One hundred twenty-three pa-
tients were male (51%), and peripheral blood stem cells were
used in 178 patients (74%). Donors were matched related
(n ¼ 155, 64%) or matched unrelated (n ¼ 87, 36%). Median
follow-up of survivors was 65 months (range, 12 to 145).
The number of patients in each of the 4 groups based on
age and remission status as previously deﬁned was as fol-
lows: 116 patients (48%) transplanted in CR1 age <60, 78
patients (32%) in CR2 age <60, 32 patients (13%) in CR1
age 60, and 16 patients (7%) in CR2 age 60. Among the
study patients, 170 (70%) received myeloablative condition-
ing regimens and 72 patients (30%) RIC regimens. Of the 48
patients60 years of age, 46 (96%) received RIC regimens. Of
the 194 patients <60 years of age, 26 (13%) received RIC
regimens.
Primary Endpoints
Overall survival
Univariate comparison between the 4 groups divided by
age/remission status (<60 in CR1, <60 in CR2, 60 in CR1,
and 60 in CR2) demonstrated a signiﬁcant difference in
survival (P ¼ .003) (Figure 1a). OS at 3 years for the 4 groups
was 57% (95% conﬁdence interval [CI], 48% to 66%), 43% (95%
CI, 32% to 54%), 39% (95% CI, 22% to 56%), and 16% (95% CI, 3%
to 38%), respectively. The hazard ratios (HRs) for survival for
the groups <60 CR1, <60 CR2, and 60 CR2 compared with
group 60 CR1 were .67 (P ¼ .13), 1.03 (P ¼ .91), and 1.83
(P ¼ .08), respectively. Of the other variables studied, unre-
lated donor status carried an increased risk (P¼ .04; HR,1.44)
and an HCT-comorbidity index score3 (P¼ .02; HR,1.55). In
the univariate analysis, cytogenetic risk at diagnosis, gender,
cytomegalovirus serostatus, graft source, conditioning in-
tensity, and year of transplant during/after 2006 were not
statistically signiﬁcant for OS.
A limited multivariable analysis was performed for OS
using the parameters age/remission status, donor type,
conditioning regimen, HCT-comorbidity index score, and
year of transplant during/after 2006. Age/remission status
group had a signiﬁcant effect on OS (overall P ¼ .02). HRs for
the groups <60 CR1, <60 CR2, and 60 CR2 in reference to
group 60 CR1 were .47, .61, and 1.52, respectively. Trans-
plant performed during/after 2006 inﬂuenced OS favorably
(P ¼ .04; HR, .67). Donor status, conditioning regimen, and
Table 1
Baseline Patient, Disease, and Transplant-Related Characteristics as Well as Comparison of Distributions of These Characteristics among 4 Groups Deﬁned by Age
and Remission Status
Characteristics All Patients (N ¼ 242) Age <60 CR1 (n ¼ 116) Age <60 CR2 (n ¼ 78) Age  60 CR1 (n ¼ 32) Age  60 CR2 (n ¼ 16) P
Age, median in years (range) 48 (18-71) 44 (18-59) 45 (18-59) 63 (60-71) 65.5 (60-70)
Gender .35
Male 123 (51%) 60 (52%) 37 (47%) 20 (63%) 6 (37%)
Female 119 (49%) 56 (48%) 41 (53%) 12 (37%) 10 (63%)
HCT-comorbidity index score .0002
0-2 171 (70%) 95 (82%) 45 (58%) 24 (75%) 7 (44%)
3 71 (30%) 21 (18%) 33 (42%) 8 (25%) 9 (56%)
Cytogenetic risk* .15
Favorable 18 (7%) 8 (7%) 9 (11%) 0 (0%) 1 (6%)
Intermediate 107 (44%) 50 (43%) 31 (40%) 17 (51%) 9 (56%)
Unfavorable 55 (23%) 32 (28%) 14 (18%) 8 (25%) 1 (6%)
Unknown/ND 62 (26%) 26 (22%) 24 (31%) 7 (22%) 5 (31%)
Graft <.0001
Bone marrow 64 (26%) 36 (31%) 28 (36%) 0 (0%) 0 (0%)
Peripheral blood 178 (74%) 80 (69%) 50 (64%) 32 (100%) 16 (100%)
CMV donor/recipient .51
Neg/neg 78 (33%) 38 (33%) 28 (37%) 9 (28%) 3 (19%)
Others 160 (67%) 77 (67%) 47 (63%) 23 (72%) 13 (81%)
Donor type <.0001
Related 155 (64%) 93 (80%) 27 (35%) 27 (84%) 8 (50%)
Unrelated 87 (36%) 23 (20%) 51 (65%) 5 (16%) 8 (50%)
Conditioning intensity <.0001
MAC 170 (70%) 103 (89%) 65 (83%) 2 (6%) 0 (0%)
RIC 72 (30%) 13 (11%) 13 (17%) 30 (94%) 16 (100%)
HCT year .001
Before 2006 147 (61%) 84 (72%) 42 (54%) 16 (50%) 5 (31%)
2006 or after 95 (39%) 32 (28%) 36 (46%) 16 (50%) 11 (69%)
ND indicates not determined; CMV, cytomegalovirus; MAC, myeloablative conditioning.
* At diagnosis as deﬁned by Southwest Oncology Group/Eastern Cooperative Oncology Group criteria [13].
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Leukemia-free survival
A univariate comparison between the 4 groups divided by
age/remission status (<60 in CR1,<60 in CR2,60 in CR1, and
60 in CR2) demonstrated a signiﬁcant difference in LFS be-
tween the respective groups (P ¼ .0005) (Figure 1b). The HRs
for LFS for the groups <60 CR1, <60 CR2, and 60 CR2
comparedwithgroup60CR1were .60 (P¼ .04), .96 (P¼ .87),
and 1.74 (P¼ .09), respectively. Concerning the other variables
studied, only an HCT-comorbidity index score  3 demon-
strated a marginally signiﬁcant impact (P ¼ .04; HR, 1.4; 95%
CI,1.02 to2.03). LFS at 3 years for the 4groupswas 57% (95%CI,
48% to 66%), 37% (95% CI, 26% to 48%), 34% (95% CI,18% to 50%),
and 13% (95% CI, 2% to 33%), respectively (Figure 1B).Figure 1. (A) OS after univariate analysis, stratiﬁed by CR status and agMultivariable analysis performed for LFS was based on
age/remission status, donor type, conditioning regimen,
HCT-comorbidity index score, and year of transplant during/
after 2006. LFS was signiﬁcantly inﬂuenced by age/remission
status group (P ¼ .02). HRs for the groups <60 CR1, <60 CR2,
and 60 CR2 in reference to group 60 CR1 were .46, .66,
and 1.51, respectively. The other variables had no signiﬁcant
effect on LFS (Table 2).
Nonrelapse mortality
The 3-year cumulative incidence of NRM in the 4 groups
was 29% (95% CI, 20% to 38%), 38% (95% CI, 26% to 51%), 31%
(95% CI, 8% to 55%), and 63% (95% CI, 31% to 94%), respectively
(P ¼ .04) (Figure 2A). The HR for NRM for the group 60 CR2
compared with group 60 CR1 was 2.1 (P ¼ .02). In the
univariate analysis, other factors associated with high NRMe (P ¼ .003). (B) LFS, stratiﬁed by CR status and age (P ¼ .0005).
Table 2
Multivariable Analysis for OS, LFS, CIR, and NRM
HR 95% CI P
OS
Age/CR status .02 (overall)
<60/CR1 .47 .23-.95 .03
<60/CR2 .61 .29-1.28 .19
60/CR1 1.00 d d
60/CR2 1.52 .76-3.04 .23
Donor
Related 1.00 d
Unrelated 1.50 .99-2.26 .05
Regimen
MAC 1.00 d
RIC .75 .43-1.30 .31
HCT-comorbidity index
0-2 1.00 d
3 1.36 .93-1.97 .11
HCT year
Before 2006 1.00 d
2006 or after .67 .46-.99 .04
LFS
Age/CR status .02 (overall)
<60/CR1 .46 .23-.91 .03
<60/CR2 .66 .32-1.35 .25
60/CR1 1.00 d d
60/CR2 1.51 .77-2.94 .23
Donor
Related 1.00 d
Unrelated 1.34 .89-2.00 .16
Regimen
MAC 1.00 d
RIC .82 .47-1.41 .46
HCT-comorbidity index .27
0-2 1.00 d
3 1.23 .85-1.77
HCT year .09
Before 2006 1.00 d
2006 or after .72 .50-1.05
CIR
Age/CR status .98 (overall)
<60/CR1 1.03 .39-2.70 .95
<60/CR2 1.61 .62-4.16 .33
60/CR1 1.00 d d
60/CR2 .90 .33-2.41 .83
Donor .20
Related 1.00
Unrelated .67 .36-1.24
Regimen .01
MAC 1.00
RIC 2.88 1.33-6.21
HCT-comorbidity index .34
0-2 1.00
3 .73 .39-1.38
HCT year .17
Before 2006 1.00 d
2006 or after 1.43 .85-2.40
Cumulative incidence of NRM
Age/CR status .01 (overall)
<60/CR1 .32 .13-.80 .01
<60/CR2 .38 .15-.99 .05
60/CR1 1.00 d d
60/CR2 2.08 .98-4.41 .06
Donor
Related 1.00 d
Unrelated 1.91 1.11-3.26 .02
Regimen .01
MAC 1.00 d
RIC .33 .16-.70
HCT-comorbidity index .13
0-2 1.00 d
3 1.42 .91-2.24
HCT year .01
Before 2006 1.00 d
2006 or after .43 .26-.71
MAC indicates myeloablative conditioning.
Dashes indicate the reference group which the other groups within the
variable are compared to.
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to 2.32) and an HCT-comorbidity index score3 (P¼ .03; HR,
1.63; 95% CI, 1.06 to 2.51). Year of transplant during/after
2006 was associated with less NRM (P ¼ .02; HR, .60; 95% CI,
.38 to .93).
Multivariable analysis (using the previously mentioned
for OS and LFS parameters) showed that age/remission status
group had a signiﬁcant effect on NRM (overall P ¼ .01; HR for
60 CR2 was 2.08 in reference to group  60 CR1, P ¼ .06).
Use of RIC regimens was associated with signiﬁcantly
decreased NRM (P ¼ .01; HR, .33), as was transplant per-
formed during/after 2006 (P ¼ .01; HR, .43). Unrelated donor
transplant was associated with increased NRM (P ¼ .02; HR,
1.91) (Table 2).
Relapse
In a univariate analysis, 3-year CIR in the 4 groups were
14% (95% CI, 6% to 22%), 24% (95% CI, 10% to 39%), 34% (95% CI,
14% to 55%), and 31% (95% CI, 10% to 56%), respectively
(P ¼ .05) (Figure 2b). The HR for CIR for the group  60 CR2
compared with group  60 CR1 was .78 (P ¼ .63). Univariate
analysis demonstrated use of RIC regimens to be associated
with a signiﬁcant increase in CIR (P< .01; HR, 2.6; 95% CI,1.52
to 4.29). Multivariable analysis (using the previously
mentioned for OS, LFS, and NRM parameters) showed that
age/remission status group had no signiﬁcant effect on CIR
(overall P ¼ .98), whereas RIC regimens were associated with
signiﬁcantly increased CIR (P ¼ .01; HR, 2.88) (Table 2).
Causes of Poor Outcome in Patients 60 Years in CR2
We attempted to study in detail the reasons for poor
outcome in patients aged 60 years in CR2 by a detailed
chart review (n ¼ 16) (Table 3). We were particularly inter-
ested in understanding whether those transplants could
have been performed in CR1. Of the 16 patients transplanted
in CR2, 9 patients were not referred for transplant in CR1. Of
the remaining 7 patients, there was no indication for trans-
plant in CR1 in 2 patients as per established indications for
transplant in our program, 1 patient refused transplant in
CR1, and 4 patients relapsed while waiting for transplant.
DISCUSSION
With the availability of RIC in the last 15 years, allogeneic
transplants in older patients with AML has been increasingly
used [1]. Although several prospective studies have de-
monstrated the beneﬁt of transplant over conventional
chemotherapy in younger patients in CR1, such prospective
comparative data in older patients are not available. Several
single-center and large registryebased studies have
demonstrated the feasibility and efﬁcacy of allogeneic
transplantation in older patients with AML. However, which
older patients are likely to beneﬁt from allogeneic trans-
plants is not entirely clear. In the absence of prospective
comparative data of allogeneic transplants versus conven-
tional chemotherapy alone, many centers use similar in-
dications for transplant as those used in younger patients.
In this study, we evaluated and compared the outcomes
of older patients with younger patients based on remission
status. We demonstrate that HCT can produce long-term
disease control and possibly cure in about one third of pa-
tients 60 years in CR1; however, such beneﬁt was lacking
in older patients in CR2. None of the patients transplanted
in CR2 survived in the long term. The main cause of failure
in older patients in CR2 was high NRM, and the HR for NRM
was >2 times compared with older patients in CR1
Figure 2. (A) Cumulative incidence rate of NRM, stratiﬁed by CR status and age (P ¼ .04). (B) CIR rate, stratiﬁed by CR status and age (P ¼ .05).
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damage resulting from multiple rounds of intensive
chemotherapy as well as infectious complications. Our data
also show that burden of comorbidities increases with
disease beyond CR1. The proportion of patients with HCT-
comorbidity index score  3 in age < 60 years CR1, age
60 years CR1, age < 60 years CR2, and age 60 years CR2
was 18%, 25%, 42%, and 56%, respectively (Table 1). This may
partially explain the high NRM in older patients in CR2,
because an increased HCT-comorbidity index score has
been associated with worse outcomes for AML in CR2 [12].
On the other hand, selected older patients with a low HCT-
comorbidity index score have demonstrated the feasibility
of transplant in an older AML population, although most of
these patients underwent HCT in CR1 [19].
We also tried to explore the reasons for older patients
undergoing transplant in CR2. One of the main reasons was
that some patients were not referred for transplant in CR1.
Some physicians are still reluctant to refer older patients for
transplant in CR1. We recommend that the option ofTable 3
Detailed Characteristics of the 16 Patients Aged  60 Years Transplanted in CR2
Patients
(n ¼ 16)
Age Cytogenetic
Risk*
Primary vs.
Secondary AML
Donor
Type
Duration
CR1 (mo)
Reason Transp
Performed in C
1 60 Intermediate Primary MUD 16 Not referred
2 60 Intermediate Primary Related 17 Not referred
3 62 Intermediate Primary MUD 61 Not referred
4 62 Unknown Primary Related 4 Relapsed whil
for HCT
5 63 Intermediate Primary Related 8 Patient refused
6 64 Intermediate Primary MUD 80 Not referred
7 64 Unavailable Secondary Related 15 Not referred
8 65 Unavailable Secondary MUD 6 Relapsed whil
for HCT
9 66 Favorable Primary Related 22 Favorable cyto
10 66 Intermediate Primary MUD 16 Favorable mol
11 66 Unavailable Secondary Related 14 Not referred
12 67 Intermediate Primary Related 4 Relapsed whil
for HCT
13 68 Unfavorable Primary MUD 4 Relapsed whil
for HCT
14 69 Intermediate Primary MUD 64 Not referred
15 70 Intermediate Primary Related 8 Not referred
16 70 Unknown Primary MUD 56 Not referred
MUD indicates matched unrelated donor; GVHD, graft-versus-host disease.
* Southwest Oncology Group/Eastern Cooperative Oncology Group criteria [13].transplant should be offered to appropriate older patients in
CR1, and the decision to proceed or defer transplant in CR1
should be made after consultation with a transplant center.
The second important cause in our dataset was disease
relapse while waiting for transplant. This indicates the need
for urgent transplantation because remissions may not be
durable in some patients. With the increasing utilization of
transplant services, there has been a tremendous strain on
health care resources. Challenges have been seen in the
capacity-building issues to funding and human resources.
With the increase in the aging population, these issues will
have to be addressed in a meaningful way so for eligible
patients the option of transplant can be provided in a timely
fashion. Alternative graft sources in older patients such as
cord blood [20] or haploidentical donors may prove to be
useful in the setting of a clinical trial.
A question arises from these data: Should older patients
in CR2 be denied the option of transplant? We recommend
caution in the interpretation of these data, because they are
not sufﬁcient in denying this option. However, these data arelant Not
R1
HCT-Comorbidity
Index Score
Time to
Death (mo)
Cause of Death
Post-Transplant
4 11 GVHD
5 2 GVHD
3 16 Aspergillosis, GVHD
e waiting 1 27 Pneumonia
HCT in CR1 1 17 Relapse
4 7 Graft failure
3 9 Metastatic breast cancer
e waiting 4 3 Relapse
genetics 0 13 NRM related to progressive
parkinsonism
ecular proﬁle 2 12 Sepsis
3 41 Cardiac
e waiting 0 38 Relapse
e waiting 2 5 Relapse
3 4 Sepsis
1 11 Relapse
4 3 Sepsis
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early referral of eligible older patients for transplant. Patients
who are unlikely to beneﬁt from transplant should be
enrolled in novel clinical trials, and several new encouraging
approaches are in progress in patients with AML.
In summary, our data demonstrate that patients 
60 years with AML in CR1 derive beneﬁt from the curative
potential of HCT. However, mainly due to high NRM, patients
60 years in CR2 would have to be carefully selected with
minimal comorbidities if any beneﬁt is to be expected with
HCT. Close collaboration between leukemia physicians and
transplant centers is needed, and if HCT is indicated in pa-
tients 60 years, attempts should be made to deliver the
transplant in CR1.
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